Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
Categorynews

NOTICE TO DISREGARD — Avicanna Inc.

March 15, 2021 Off By GlobeNewswire

TORONTO, March 15, 2021 (GLOBE NEWSWIRE) — We are advised by Avicanna Inc. that journalists and other readers should disregard the news release, “Avicanna to present at the Q1 Virtual Investor Summit” issued March 11, 2021, over GlobeNewswire.

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email a link to a friend (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)

Related

TagsCA05368k1003 Frankfurt:ONN OTC Markets:AVCNF TSX:AVCN
Anchiano Announces Shareholder Approval of the Merger with Chemomab and Prices $45.5M Private Financing
Purdue Pharma L.P. Files Broadly Supported Plan of Reorganization

Popular posts

Medicago, GSK report primary and secondary endpoints with available data met in trial dominated by COVID-19 variants

December 10, 2021 Off

Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)

December 5, 2025 Off
Cosentyx meets the primary endpoints

Cosentyx meets the primary endpoints

June 15, 2015 Off
Adapt Pharma rolls submision to NDA for naloxone-based nasal spray

Adapt Pharma rolls submision to NDA for naloxone-based nasal spray

June 15, 2015 Off
Strensiq in HPP patiens therapy get approval from European Commission

Strensiq in HPP patiens therapy get approval from European Commission

September 13, 2015 Off

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine
Go to mobile version